Selectivity for inhibition of nilotinib on the catalytic activity of human UDP-glucuronosyltransferases

Xenobiotica

Volumn 44, Issue 4, 2014, Pages 320-325

  Ai, Limei ^a   Zhu, Liangliang ^b   Yang, Lu ^c   Ge, Guangbo ^d   Cao, Yunfeng ^d   Liu, Yong ^d   Fang, Zhongze ^d   Zhang, Yanyan ^d  

^a JINZHOU MEDICAL UNIVERSITY   (China)

^b ANQING NORMAL UNIVERSITY   (China)

^c LIAONING UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^d DALIAN INSTITUTE OF CHEMICAL PHYSICS   (China)

Author keywords

Niloinib; The selective inhibitor; UDP glucuronosyltransferase 1A1

Indexed keywords

ESTRADIOL; ESTRADIOL 3 O GLUCURONIDE; FIRTECAN; GLUCURONIDE; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A7; HYMECROMONE; HYMECROMONE GLUCURONIDE; NILOTINIB; UNCLASSIFIED DRUG;

ARTICLE; CATALYSIS; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG GLUCURONIDATION; DRUG INHIBITION; DRUG POTENCY; DRUG SELECTIVITY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; LIVER MICROSOME; NORMAL HUMAN;

CATALYSIS; ENZYME INHIBITORS; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HUMANS; KINETICS; LIVER; MICROSOMES, LIVER; PHENOTYPE; PYRIMIDINES; RECOMBINANT PROTEINS;

EID: 84896773613     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2013.840750     Document Type: Article

References (20)

1. Bosma PJ, Seppen J, Goldhoorn B, et al. (1994). Bilirubin UDP-glucuronosyltransferase 1 is the only relevant bilirubin glucuronidating isoform in man. J Biol Chem 269:17960-4. (Pubitemid 24206189)
2. Court MH, Krishnaswamy S, Hao Q, et al. (2003). Evaluation of 30-azido-30-deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism. Drug Metab Dispos 31:1125-33. (Pubitemid 37048284)
3. Court MH. (2010). Interindividual variability in hepatic drug glucuronidation: studies into the role of age, sex, enzyme inducers, and genetic polymorphism using the human liver bank as a model system. Drug Metab Rev 42:209-24.
4. Fujita K, Sugiyama M, Akiyama Y, et al. (2011). The small-molecule tyrosine kinase inhibitor nilotinib is a potent noncompetitive inhibitor of the SN-38 glucuronidation by human UGT1A1. Cancer Chemother Pharmacol 67:237-41.
5. Izukawa T, Nakajima M, Fujiwara R, et al. (2009). Quantitative analysis of UDP-glucuronosyltransferase (UGT) 1A and UGT2B expression levels in human livers. Drug Metab Dispos 37:1759-68.
6. Liu Y, Ram?́rez J, House L, Ratain MJ. (2010). Comparison of the drug-drug interactions potential of erlotinib and gefitinib via inhibition of UDP-glucuronosyltransferases. Drug Metab Dispos 38:32-9.
7. Liu Y, Ram?́rez J, Ratain MJ. (2011). Inhibition of paracetamol glucuronidation by tyrosine kinase inhibitors. Br J Clin Pharmacol 71:917-20.
8. Mackenzie PI, Bock KW, Burchell B, et al. (2005). Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet Genomics 15:677-85. (Pubitemid 41345319)
9. Miners JO, Bowalgaha K, Elliot DJ, et al. (2011). Characterization of niflumic acid as a selective inhibitor of human liver microsomal UDP-glucuronosyltransferase 1A9: application to the reaction phenotyping of acetaminophen glucuronidation. Drug Metab Dispos 39:644-52.
10. Miners JO, Mackenzie PI, Knights KM. (2010). The prediction of drug-glucuronidation parameters in humans: UDPglucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro-in vivo extrapolation of drug clearance and drug-drug interaction potential. Drug Metab Rev 42:196-208.
11. Nishiyama T, Kobori T, Arai K, et al. (2006). Identification of human UDP-glucuronosyltransferase isoform(s) responsible for the C-glucuronidation of phenylbutazone. Arch Biochem Biophys 454: 72-9. (Pubitemid 44427739)
12. Soars MG, Ring BJ, Wrighton SA. (2003). The effect of incubation conditions on the enzyme kinetics of udp-glucuronosyltransferases. Drug Metab Dispos 31:762-7. (Pubitemid 36617665)
13. Spraggs CF, Xu CF, Hunt CM. (2013). Genetic characterization to improve interpretation and clinical management of hepatotoxicity caused by tyrosine kinase inhibitors. Pharmacogenomics 14: 541-54.
14. Tukey RH, Strassburg CP. (2001). Genetic multiplicity of the human UDP-glucuronosyltransferases and regulation in the gastrointestinal tract. Mol Pharmacol 59:405-14. (Pubitemid 32179916)
15. Uchaipichat V, Mackenzie PI, Elliot DJ, Miners JO. (2006a). Selectivity of substrate (trifluoperazine) and inhibitor (amitriptyline, androsterone, canrenoic acid, hecogenin, phenylbutazone, quinidine, quinine, and sulfinpyrazone) "probes" for human udp-glucuronosyltransferases. Drug Metab Dispos 34:449-56.
16. Uchaipichat V, Mackenzie PI, Guo XH, et al. (2004). Human udp-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid. Drug Metab Dispos 32:413-23. (Pubitemid 38420275)
17. Uchaipichat V, Winner LK, Mackenzie PI, et al. (2006b). Quantitative prediction of in vivo inhibitory interactions involving glucuronidated drugs from in vitro data: the effect of fluconazole on zidovudine glucuronidation. Br J Clin Pharmacol 61:427-39.
18. Williams JA, Hyland R, Jones BC, et al. (2004). Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos 32:1201-8. (Pubitemid 39410902)
19. Zhou J, Tracy TS, Remmel RP. (2011). Correlation between bilirubin glucuronidation and estradiol-3-gluronidation in the presence of model UDP-glucuronosyltransferase 1A1 substrates/inhibitors. Drug Metab Dispos 39:322-9.
20. Zhu L, Ge G, Liu Y, et al. (2012). Potent and selective inhibition of magnolol on catalytic activities of UGT1A7 and 1A9. Xenobiotica 42:1001-8.